Wren Therapeutics
Dr. von Eschenbach was appointed acting Commissioner of the U.S. Food and Drug Administration in 2005, was later confirmed by the Senate as Commissioner in 2006, and then held the role until his resignation in 2009. Prior to that, Dr. von Eschenbach served as director of the National Cancer Institute at the National Institutes of Health from 2002 to 2006. Dr. von Eschenbach also previously served as a physician, surgeon, oncologist and executive, from Chairman of the Department of Urologic Oncology to Executive Vice President and Chief Academic Officer at the University of Texas M.D. Anderson Cancer Center from 1976 until 2002, and since 2009, he has continued to serve as an adjunct professor there. Dr. von Eschenbach also currently serves on the Board of Directors of Bausch Health plc, as president of Samaritan Health Initiative, senior fellow at the Bipartisan Policy Centre, and as a senior fellow at the Milken Institute. In 2006, Dr. von Eschenbach was named to the “Time 100,” the magazine’s annual list of the 100 most influential people to shape the world. Additionally, Dr. von Eschenbach was selected in both 2007 and 2008 as one of the Modern Healthcare/Modern Physician’s “50 Most Powerful Physician Executives in Healthcare.” Dr. von Eschenbach is the author of more than 300 scientific articles and studies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Wren Therapeutics
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.